Demonstrating our scientific excellence and commitment to rheumatology: UCB at EULAR 2015
Posted by
15-Jun-2015
UCB sponsored multiple presentations across a spectrum of rheumatic diseases at the European League Against Rheumatism Annual Congress (EULAR 2015) in Rome, Italy, last week (10th – 13th June 2015). The UCB-sponsored clinical and scientific presentations at EULAR 2015 highlight our dedication to scientific excellence and improving the lives of people with severe diseases.
According to the Congress planners, EULAR is the most important platform in Europe for exchanging scientific and clinical information on rheumatology. Approximately 14,000 scientists, physicians, allied health professionals and related audiences attended from more than 120 countries.
EULAR is an important opportunity for UCB to share the latest research from its pipeline on rheumatic diseases.
One key presentation was the Phase 3 investigational data assessing the efficacy and safety of one of our core medicines used to treat rheumatoid arthritis in combination with optimized methotrexate in patients with severe, active and progressive rheumatoid arthritis who have not been treated with disease modifying anti-rheumatic drugs (DMARD-naïve).
Pre-clinical data was also shown on an investigational medicine in Phase 3 clinical development for systemic lupus erythematosus (SLE) and on an investigational medicine for immune-inflammatory diseases.
UCB also sponsored two satellite symposia, one on the importance of appropriately timing treatment initiation in RA patients and the other on optimal management of spondyloarthritis.
Rheumatic diseases affect hundreds of millions of people around the world and are the most common cause of severe long-term pain and physical disability. The burden of rheumatic diseases on people and society is expected to increase dramatically over the next decade, largely due to an increasingly ageing population and lifestyle changes throughout the world.1
The pain and disability caused by rheumatic disease can have an impact on emotional well-being and mental health. Rheumatic diseases not only affect the people suffering from them but also their families who bear significant burden in terms of high financial costs, time and personal commitment to ensure relatives receive the necessary care and treatment.1
The serious impact of rheumatic disease is the reason UCB continues its commitment to research in this disease area and providing value to patients living with these conditions.
Reference
According to the Congress planners, EULAR is the most important platform in Europe for exchanging scientific and clinical information on rheumatology. Approximately 14,000 scientists, physicians, allied health professionals and related audiences attended from more than 120 countries.
EULAR is an important opportunity for UCB to share the latest research from its pipeline on rheumatic diseases.
One key presentation was the Phase 3 investigational data assessing the efficacy and safety of one of our core medicines used to treat rheumatoid arthritis in combination with optimized methotrexate in patients with severe, active and progressive rheumatoid arthritis who have not been treated with disease modifying anti-rheumatic drugs (DMARD-naïve).
Pre-clinical data was also shown on an investigational medicine in Phase 3 clinical development for systemic lupus erythematosus (SLE) and on an investigational medicine for immune-inflammatory diseases.
UCB also sponsored two satellite symposia, one on the importance of appropriately timing treatment initiation in RA patients and the other on optimal management of spondyloarthritis.
Rheumatic diseases affect hundreds of millions of people around the world and are the most common cause of severe long-term pain and physical disability. The burden of rheumatic diseases on people and society is expected to increase dramatically over the next decade, largely due to an increasingly ageing population and lifestyle changes throughout the world.1
The pain and disability caused by rheumatic disease can have an impact on emotional well-being and mental health. Rheumatic diseases not only affect the people suffering from them but also their families who bear significant burden in terms of high financial costs, time and personal commitment to ensure relatives receive the necessary care and treatment.1
The serious impact of rheumatic disease is the reason UCB continues its commitment to research in this disease area and providing value to patients living with these conditions.
Reference
- EULAR 2015. European League Against Rheumatism Annual Congress. Rheumatic diseases factsheet. Accessed at: http://www.congress.eular.org/myUploadData/files/EULAR%202015%20Rheumatic%20Diseases%20Factsheet.pdf
Leave a Comment
When will 1st results for Epratuzumab be available?
Dear Sir, the top-line results of our Phase 3 studies in lupus (epratuzumab) will be shared this summer. Kind regards. UCB